GAO restated its controversial 2015 finding that 340B covered entities prescribe more drugs or more expensive drugs than necessary.
Government Watchdog Reissues Controversial Finding on Adverse Incentives in 340B Program
The U.S. Government Accountability Office late last month restated its controversial recommendation that Congress take actions to reduce incentives for [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
